Literature DB >> 8427038

Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis.

M P Jiménez de Bagüés1, C M Marín, M Barberán, J M Blasco.   

Abstract

A mouse model was developed to study Brucella ovis infection. The evolution of the number of B. ovis per spleen of mice inoculated intravenously, intraperitoneally or subcutaneously was found to be independent of the sex of the mice. The number of B. ovis increased in the spleen when increasing the challenge dose up to 1.7 x 10(7). At higher doses of challenge, the response remained constant. In this model it was observed that the inoculation of Brucella melitensis Rev 1 vaccine or subcellular B. ovis hot saline antigens during both the acute and chronic phases did not modify the time course of B. ovis infection. Finally, the model was found suitable to determine the efficacy of anti-B. ovis vaccines. B. melitensis Rev 1 (2.2 x 10(5) c.f.u.) and B. suis strain 2 (1.2 x 10(7) c.f.u.) live vaccines but not the inactivated B. melitensis H38 vaccine conferred protection against B. ovis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427038     DOI: 10.1016/0264-410x(93)90340-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Analysis of the behavior of eryC mutants of Brucella suis attenuated in macrophages.

Authors:  Sonja Burkhardt; Maria P Jiménez de Bagüés; Jean-Pierre Liautard; Stephan Köhler
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Putative ATP-binding cassette transporter is essential for Brucella ovis pathogenesis in mice.

Authors:  Teane M A Silva; Tatiane A Paixão; Erica A Costa; Mariana N Xavier; Joicy Cortez Sá; Valéria S Moustacas; Andreas B den Hartigh; Alcina V Carvalho Neta; Sérgio C Oliveira; Renée Tsolis; Renato L Santos
Journal:  Infect Immun       Date:  2011-02-07       Impact factor: 3.441

3.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

4.  Role of the Omp25/Omp31 family in outer membrane properties and virulence of Brucella ovis.

Authors:  Paola Caro-Hernández; Luis Fernández-Lago; María-Jesús de Miguel; Ana I Martín-Martín; Axel Cloeckaert; María-Jesús Grilló; Nieves Vizcaíno
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

5.  Different responses of macrophages to smooth and rough Brucella spp.: relationship to virulence.

Authors:  María P Jiménez de Bagüés; Annie Terraza; Antoine Gross; Jacques Dornand
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

Review 6.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

Review 7.  When the Going Gets Rough: The Significance of Brucella Lipopolysaccharide Phenotype in Host-Pathogen Interactions.

Authors:  Lauren W Stranahan; Angela M Arenas-Gamboa
Journal:  Front Microbiol       Date:  2021-07-15       Impact factor: 5.640

8.  Disruption of pyruvate phosphate dikinase in Brucella ovis PA CO2-dependent and independent strains generates attenuation in the mouse model.

Authors:  Nieves Vizcaíno; Lara Pérez-Etayo; Raquel Conde-Álvarez; Maite Iriarte; Ignacio Moriyón; Amaia Zúñiga-Ripa
Journal:  Vet Res       Date:  2020-08-14       Impact factor: 3.683

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.